Last updated on November 2019

ANAVEX2-73 for Treatment of Early Alzheimer's Disease


Brief description of study

Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73.

Detailed Study Description

This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Additional outcome measures include refined measures of sleep, behavioral and psychological symptoms typically observed in AD, changes in daily functioning of participants and changes in caregiver burden, as well as changes in quality of life measures of both, patients and caregivers during treatment with ANAVEX2-73. In addition, safety assessments, pharmacokinetic (PK) assessments and collections of CSF and blood markers of AD pathophysiology before and after treatment will be performed.

Clinical Study Identifier: NCT03790709

Find a site near you

Start Over

St Vincent Hospital Sydney

Sydney, Australia
4.64miles
  Connect »

University of Sydney

Sydney, Australia
4.64miles
  Connect »

KaRa MINDS

Macquarie Park, Australia
5.82miles
  Connect »